Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ablynx NV
AdAlta To Raise Funds To Take Shark-Derived Fibrosis Candidate Into Clinic
Australian biotech company AdAlta develops protein therapeutics based on shark antibodies, much the same way as Ablynx and others use camelid antibodies. It has just applied to raise an IPO on the Australian Securities Exchange [ASX] to fund clinical studies with its lead compound AD-114 which shows promise in treating fibrosis.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablynx NV
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice